Nonalcoholic fatty liver disease (NAFLD) is a silent disease, characterized by fat accumulation in the liver that's not caused by alcohol. NAFLD can progress to nonalcoholic steatohepatitis (NASH), with inflammation and damage to liver cells. It displays few symptoms and there's little understanding of its pathogenesis. By the time individuals with NASH become aware of symptoms, it can be too late to reverse.
There are currently no approved treatments for NAFLD or NASH, and diagnosis remains challenging. But studies show that fat and scar tissue can leave the liver, suggesting that NAFLD and NASH are reversible. That's where we can help - PerkinElmer offers a comprehensive portfolio of tools to enable further understanding of NASH pathophysiology, help identify new therapeutic targets, and characterize novel drug therapies.